IgPro20

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Multiple MyelomaImmune Deficiency

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

1

Keytruda

Merck & Co.

Phase 3

172

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

293

Opdivo

Bristol-Myers Squibb

Phase 3

114

Treanda

AAzurity Pharmaceuticals

Phase 3

195

Neulasta

Amgen

Phase 3

56

Vepesid

AAvyxa

Phase 3

177

Cytosar

Teva

Phase 3

48

Busulfex

Akero Therapeutics

Phase 3

159

BLENREP

GGlaxo Dba Glaxosmithkline

Phase 3

1010

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

9Show 28 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Chronic Inflammatory Demyelinating Polyneuropathy2 trials

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

Completed·CSL Behring·Phase 3·NCT01545076·208 enrolled

Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Completed·CSL Behring·Phase 3·NCT02027701·82 enrolled

Immunodeficiency2 trials

Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)

Completed·CSL Behring·Phase 3·NCT00719680·21 enrolled

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

Completed·CSL Behring·Phase 4·NCT03033745·49 enrolled

Immune1 trial

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Completed·CSL Behring·Phase 3·NCT00751621·40 enrolled

Systemic Sclerosis1 trial

Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)

Completed·CSL Behring·Phase 2·NCT04137224·27 enrolled

COVID-191 trial

Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

Terminated·CSL Behring·Phase 3·NCT06524739·16 enrolled

2 more indications

Multiple Myeloma1 trial

Prospective Randomized Phase II Study Evaluating Efficacy and Safety of IgPro20 as Infection Prophylaxis in Patients With Multiple Myeloma and Hypogammaglobulinemia Receiving Therapy With a Bispecific Monoclonal Antibody (BsAbs)

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06976476·100 enrolled

Immune Deficiency1 trial

A Phase 3, Prospective, Open-label, Multicenter, Single-arm Study to Investigate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Subjects With Secondary Immune Deficiency Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Recruiting·CSL Behring·Phase 3·NCT07648264·63 enrolled

Details

Drug Info

Related News